title: [Results of radiotherapy in patients with bladder carcinoma].
abstract: The authors analyse the results of treatment with radiotherapy with therapeutic doses and traditional fractionation scheme 60 patients affected by bladder cancer, from 1980 through 1991, at the Institute of Radiology of the University "La Sapienza" in Rome. We evaluated the association of radiotherapy (RT) with trans-urethral resection and biopsy (TURB) and the association of RT with cystectomy (total or partial), both in T1-T2 and T3-T4 bladder stages. The mean follow-up was 85 months (from 24 months to 11 years). The survival at 5 years after completing the treatment was 33.3%; the survival of stages T1-T2 was of 40% at 5 years while that of stages T3-T4 was of 28.5%. Our study shows that the association of radiotherapy and TURB for T1 or T2 bladder cancer is an alternative to mutilating surgery like total or partial cystectomy; in this group, indeed, we showed a survival of 54.5% at 5 years as compared to the 28.5% of the group treated with cystectomy + RT. For T3 and T4 bladder cancer we had better results with surgery (total or partial cystectomy) and RT: in these patients the survival at 5 years was of 31%, while the group treated with TURB + RT showed a survival of 19%.
authors: Divisione di Radioterapia Oncologica, Università degli Studi di Roma La Sapienza, Roma.
authors: V
authors: V
authors: Tombolini
authors: E
authors: E
authors: Banelli
authors: P
authors: P
authors: Zotti
authors: M
authors: M
authors: Osti
authors: A
authors: A
authors: Zurlo
authors: C
authors: C
authors: Guidi
authors: R M
authors: RM
authors: Enrici
mesh_terms: D000368:Aged; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000532:radiotherapy* / Q000601:surgery*
vernacular_title: Risultati del trattamento radioterapico nei pazienti con carcinoma vescicale.